BD Green

Effects of the novel (Pro3)GIP antagonist and exendin(9–39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin

Victor A. Gault, Finbarr O’Harte, Patrick Harriott et al. · Diabetologia · 2003 · 132 citations · Full text

Life Sciences, Endocrinology, Pharmacology +17

N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity

BD Green, MH Mooney, Nigel Irwin et al. · Journal of Endocrinology · 2004 · 57 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid

BD Green, Victor A. Gault, Peter R. Flatt et al. · Archives of Biochemistry and Biophysics · 2004 · 49 citations

Medicine, Endocrinology, Pharmacology +17

Pituitary adenylate cyclase-activating peptide (PACAP): Assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential

BD Green, Nigel Irwin, Peter R. Flatt · Peptides · 2006 · 37 citations

Medicine, Endocrinology, Pharmacology +16

Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo

BD Green, MH Mooney, Nigel Irwin et al. · Journal of Molecular Endocrinology · 2003 · 37 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17